Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Listed as NCT02572817, this PHASE3 trial focuses on Influenza A Virus Infection and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 13 times since 2015, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 8 earlier versions
-
Nov 2018 — Jul 2019 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE3
-
Jun 2017 — Jan 2018 [monthly]
Recruiting PHASE3
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Mar 2017 — Apr 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .